The Latest Cardiac and Vascular News
IRVINE, Calif., Jan. 26, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2021. Fourth Quarter Highlights and Outlook 2021 sales grew 19 percent, or 18 percent on an underlying1 basis Q4 sales grew 12 percent to $1.33 […]
ONLY HOSPITAL IN COACHELLA VALLEY TO OFFER TAVR RANCHO MIRAGE, Calif., Dec. 16, 2021 /PRNewswire/ — Eisenhower Health is the FIRST hospital in California to be recognized by Edwards Lifesciences for completing its Edwards Benchmark program for the treatment of aortic stenosis in patients undergoing […]
IRVINE, Calif., Nov. 6, 2021 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) announced that results from a clinical trial of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months. Results from the TRISCEND study, treating […]
IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This […]
IRVINE, Calif., Oct. 27, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2021. Third Quarter Highlights and 2021 Outlook Sales grew 15 percent to $1.3 billion; underlying1 sales grew 14 percent TAVR sales grew 15 percent; underlying 14 […]
IRVINE, Calif., July 29, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights and 2021 Outlook Sales rebounded and grew 49 percent to $1.4 billion; underlying1 sales grew 44 percent TAVR sales exceeded expectations […]
IRVINE, Calif., June 1, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance. This is the first noninvasive solution that unlocks Acumen HPI […]
At 1 year, outcomes similar to overall cohort of patients IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 […]
IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company’s transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by […]
AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards’ bioprosthetic surgical aortic valve with the company’s novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median […]
